Key result
Across 66 meta-analyzed studies, proton pump inhibitors taken alone or concomitantly with antiplatelets were not consistently associated with major adverse cardiovascular events.
Why the study?
While the cardiovascular risk of concomitant PPIs and clopidogrel has been debated, recent reports suggest PPIs may increase MACE risk independently of clopidogrel.
Does the use of proton pump inhibitors, alone or in combination with antiplatelet agents, increase the risk of major adverse cardiovascular events?
Population
118 studies in the systematic review and 66 in the meta-analyses
Comparison
PPIs vs no PPIs, PPIs plus clopidogrel vs clopidogrel alone, and PPIs plus other drugs vs other drugs
Design
Systematic review and meta-analysis
Authors
Loading...
Reassures on PPI safety with or without antiplatelets; challenges prior observational signals of MACE risk.
Meta-Analysis
Does the use of proton pump inhibitors, alone or in combination with antiplatelet agents, increase the risk of major adverse cardiovascular events?
This meta-analysis finds no consistent evidence that proton pump inhibitors increase the risk of major adverse cardiovascular events, either alone or when combined with antiplatelet therapy.
Farhat et al. (2019) conducted a meta-analysis in Major adverse cardiovascular events (MACE). Proton pump inhibitors (PPIs) vs. No PPIs or antiplatelets alone was evaluated on Major adverse cardiovascular events (MACE). Across 66 meta-analyzed studies, proton pump inhibitors taken alone or concomitantly with antiplatelets were not consistently associated with major adverse cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: